Sprix Nasal Spray Now Commercially Available and Warns of SJS and TEN

On May 17, Regency Therapeutics, a newly-established division of Luitpold Pharmaceuticals Inc., and its co-promotion partner, Daiichi Sankyo Inc., announced that it has launched the nasal spray Sprix (ketorolac tromethamine) and made it commercially available.

Sprix won approval by the FDA in May of last year, to be used for the short-term (up to 5 days) treatment of moderate to severe pain that would generally require an opiod-level analgesia. Sprix is considered a prescription intranasal mixture that is made up of the analgesic ketorolac tromethamine injection, which is an NSAID. Ketorolac tromethamine injections were primarily used in hospitals until now. The spray was marketed in the U.S. as Toradol by Roche Laboratories. Now that Sprix has hit the scene, this strong form of pain reliever is now available in a way that lets the user administer it to themselves in easy-to-use nasal spray form.

Sprix comes with many warnings on the label, which include Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TENS). Both conditions are potentially life threatening. TENS and SJS cause symptoms that include and lead to:

  • Rash that spreads
  • Painful blisters all over the body
  • Blisters inside of the mucus membranes (eyes, throat, ears, mouth and genitals)
  • Skin to burn off in large patches (up to 85 percent of the body)
  • Blindness
  • Liver damage
  • Death

More and more medications are being linked to SJS and TENS everyday. Since the condition is caused by a severe allergic reaction that is almost impossible to predict, it is likely that all medications will start to carry this warning in the future. But until then, contact SJS attorney Greg Jones if you or someone you love should develop SJS or TENS after using Sprix. I am an experienced SJS and TENS lawyer and I may be able to help you recover money for your injuries.

Share this article

You May Also Like

All Rights Reserved 2016